ArticleZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
Effect of subretinal injection of tissue-type plasminogen activator for the treatment of submacular hemorrhage complicating polypoidal choroidal vasculopathy.
Article in Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Vitrectomy with Low-Dose Subretinal t-PA for Hemorrhage Due to Traumatic Choroidal Rupture: A Case Series.International medical case reports journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesPolypoidal choroidal vasculopathy (PCV) is a major cause of vision loss among older adults worldwide and is particularly common in Asians. When the aneurysmal dilatation of blood vessels or the rupture of widened small veins/arteries occurs, it leads to submacular hemorrhage (SMH), which can result in irreversible damage to vision over time. This study aims to evaluate the surgical outcomes and complications of pars plana vitrectomy (PPV) combined with intraoperative subretinal injection of tissue-type plasminogen activator (t-PA) and postoperative intravitreal injection of anti-vascular endothelial growth factor (VEGF) for the treatment of SMH secondary to PCV.
methodsThirteen patients (13 eyes) with SMH secondary to PCV treated at the Eye Center, Xiangya Hospital, Central South University, from September 2020 to December 2021, were included in this study. All patients underwent PPV combined with subretinal injection of t-PA during surgery and received postoperative intravitreal injections of anti-VEGF. Best corrected visual acuity (BCVA), intraocular pressure, absorption of subretinal hemorrhage, progression of the primary lesion, surgical complications, and factors associated with postoperative efficacy were analyzed preoperatively, 1 week postoperatively, 1 month postoperatively, and 6 months postoperatively.
resultsAll patients completed the 6-month follow-up, and at the final visit, 100% of the subretinal hemorrhage of 13 patients was completely cleared. BCVA significantly improved at both 1 month and 6 months postoperatively compared to preoperative and 1-week postoperative levels (all
conclusionsPPV combined with subretinal t-PA injection and postoperative intravitreal anti-VEGF injection effectively clears SMH secondary to PVC with few surgical complications and significantly improves visual function of the patients over 6-month long-term follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.